Mesoblast Appoints Dr. Gregory George to Board, Strengthening Commercial Growth

Mesoblast Limited, a global leader in allogeneic cellular medicines for inflammatory diseases, has announced the appointment of Dr. Gregory George, MD, PhD, to its Board of Directors. As Mesoblast’s largest shareholder and the founder of SurgCenter Development, the largest privately owned ambulatory surgical center company in the U.S., Dr. George brings a wealth of experience in medical innovation and business growth. His leadership in transforming a startup into a multi-billion-dollar enterprise aligns with Mesoblast’s vision of evolving into a leading commercial biotechnology company.

Dr. George expressed confidence in Mesoblast’s potential to revolutionize healthcare with its mesenchymal stem cell therapies, which he believes could transform treatment options for conditions like arthritis and back pain. He emphasized the importance of operational excellence and proactive strategies in bringing innovative therapies to market. Mesoblast’s Founder and CEO, Dr. Silviu Itescu, and Chair Jane Bell welcomed Dr. George, citing his strategic insight as a key asset in driving the company’s global commercialization efforts.